MDT

86.09

-1.2%↓

112.63

+1.15%↑

VEEV

174.84

+0.52%↑

HQY

81.53

-0.78%↓

CSBR

5.59

-0.36%↓

MDT

86.09

-1.2%↓

112.63

+1.15%↑

VEEV

174.84

+0.52%↑

HQY

81.53

-0.78%↓

CSBR

5.59

-0.36%↓

MDT

86.09

-1.2%↓

112.63

+1.15%↑

VEEV

174.84

+0.52%↑

HQY

81.53

-0.78%↓

CSBR

5.59

-0.36%↓

MDT

86.09

-1.2%↓

112.63

+1.15%↑

VEEV

174.84

+0.52%↑

HQY

81.53

-0.78%↓

CSBR

5.59

-0.36%↓

MDT

86.09

-1.2%↓

112.63

+1.15%↑

VEEV

174.84

+0.52%↑

HQY

81.53

-0.78%↓

CSBR

5.59

-0.36%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Avatud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

11%

89%

15 / 349 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. märts 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30. märts 2026, 22:36 UTC

Uudisväärsed sündmused

Australian Government Rules Out Boots on the Ground in the Middle East

30. märts 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30. märts 2026, 21:00 UTC

Tulu

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30. märts 2026, 20:15 UTC

Uudisväärsed sündmused

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30. märts 2026, 23:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. märts 2026, 23:40 UTC

Market Talk

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30. märts 2026, 23:36 UTC

Market Talk

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30. märts 2026, 23:12 UTC

Market Talk

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30. märts 2026, 22:49 UTC

Market Talk

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30. märts 2026, 22:44 UTC

Market Talk

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30. märts 2026, 22:43 UTC

Market Talk

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30. märts 2026, 22:42 UTC

Market Talk

South32 Should Go for Growth, Says New Bull -- Market Talk

30. märts 2026, 22:18 UTC

Market Talk

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30. märts 2026, 22:05 UTC

Market Talk

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30. märts 2026, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Financial Agrees to Buy Bell Partners for $350M

30. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30. märts 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30. märts 2026, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30. märts 2026, 21:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. märts 2026, 21:25 UTC

Market Talk

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30. märts 2026, 21:03 UTC

Omandamised, ülevõtmised, äriostud

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30. märts 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. märts 2026, 20:09 UTC

Tulu

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30. märts 2026, 20:00 UTC

Uudisväärsed sündmused

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

15 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.